| September 4 |
Study Shows Combination Therapy Incorporating Avodart and
Tamsulosin Provides Continuous Symptom Improvement Over 2 Years |
| September 4 |
NeurogesX Announces Positive Results from Second Phase 3 Clinical
Trial in Postherpetic Neuralgia |
| September 4 |
Poniard Pharmaceuticals Announces Updated Results of Picoplatin
Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung
Cancer Patients |
| September 4 |
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate
Similar Safety Profile in Diabetic Patients for Cypher
Sirolimus-Eluting Coronary Stent and Taxus Stent |
| September 4 |
New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has
Sustained Efficacy Over Six Months in Adults With Chronic Insomnia |
| September 4 |
SPP100 (Tekturna/Rasilez) Promising Results in Patients with Heart
Failure |
| September 4 |
Angiox (Bivalirudin) Alone Reduced Early Bleeding and Resulted in
Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa
Combination Therapy in ACS Patients Undergoing Angioplasty |
| September 4 |
Largest Study to Date Shows Significant Reductions in Risks of
Blood Clots and Reintervention With CYPHER Sirolimus-eluting
Coronary Stent Compared to Taxus Stent |
| September 4 |
Study Published in Clinical Cancer Research Confirms Potential Of
Peregrine's Bavituximab Combined With Radiation In Lung Cancer |
| September 4 |
Clinical Data Announces Positive Results from Phase III Pivotal
Trial of Vilazodone for Depression |
| September 4 |
Data from Patient Subsets of e-HEALING, a Worldwide Registry,
Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM)
as Alternative to Drug- Eluting Stents |
| September 4 |
Cypher Sirolimus-Eluting Coronary Stent Demonstrates Sustained
Clinical Benefits Compared to Bare Metal Stents in Five-Year
Randomized Clinical Trial With No Differences in Long-Term Safety |
| September 4 |
Cell That Triggers Symptoms in Allergy Attacks Can Also Limit
Damage, Stanford Researchers Find |
| September 4 |
Investigational Agent Targeting Metabotropic Glutamate 2/3
Receptors Demonstrates Antipsychotic Activity in Humans, Study in
Nature Medicine Finds |
| September 4 |
New Study Findings Confirm Clexane/Lovenox Long-Term Clinical
Benefit in Patients Suffering From Acute Coronary Syndrome |
| September 4 |
Metabasis Therapeutics Announces Publication of Its Novel
Computer-Aided Drug Design Technology for Drug Discovery in the
Journal of the American Chemical Society |
| September 4 |
Safety Profile of Taxus Liberte Stent System Highlighted in World's
Largest Stent Registry |
| September 4 |
Over 80% of Patients on ATC Achieve Undetectable HIV After 24 Weeks |
| September 4 |
Pharmexa Presents Data from Malaria Vaccine on International
Vaccine Conference |
| September 4 |
PhytoMedical Releases Preliminary Research Results For New Class of
Diabetes Compounds |
| September 4 |
Major ADVANCE for Type 2 Diabetics |
| September 4 |
New Study Demonstrates Patients Who Were Informed of Their Risk of
Cardiovascular Disease Lowered Their Predicted Risk for Coronary
Heart Disease |
| September 4 |
Study Shows Rasilez, the First and Only Approved Direct Renin
Inhibitor, Reduces a Marker of Heart Failure Severity and is
Well-Tolerated |
| September 4 |
First PAH Functional Class II Population Study Emphasizes Need to
Diagnose and Treat PAH Early |
| September 4 |
New Data On Orexin Receptor Antagonist Almorexant Shows Therapeutic
Potential to Restore Normal Physiological Sleep in Patients
Suffering From Insomnia |
| September 4 |
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive
Patients as Demonstrated in a Study Published in the Journal of
Clinical Hypertension |
| September 4 |
Roche's Tarceva Delivers Longer Life for Lung Cancer Patients |
| September 4 |
American Heart Association Comment Saving Lives in Type 2
Diabetics: Could It Be as Easy as Lowering Blood Pressure? |
| September 4 |
Next Pharmaceuticals Announces Results of Relora Open Label Study |
| September 5 |
Depomed Announces Positive Results of Phase 2a Proof-of-Concept
GERD Study |
| September 5 |
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin in
Recurrent Non-Small Cell Lung Cancer Patients |
| September 5 |
Salix Announces Statistically Significant Top-Line Results of a
Unique Granulated Mesalamine Product Registration Study in
Ulcerative Colitis |
| September 5 |
Rifaximin Demonstrates Statistically Significant Improvement in
Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable
Bowel Syndrome in Phase IIb Study |
| September 5 |
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe
Internationale d'Urologie |
| September 5 |
Advanced Life Sciences to Present Data on Selected Cethromycin
Therapeutic Studies at the 47th Interscience Conference on
Antimicrobial Agents and Chemotherapy |
| September 5 |
Study Shows Iressa (Gefitinib) Is As Effective As Docetaxel In
Pre-Treated Advanced NSCLC |
| September 5 |
AKELA Pharma Inc. Announces Positive Results for The Extension Part
of its Phase IIb Fentanyl Taifun Trial |
| September 5 |
REACH Registry Highlights That Patients With Peripheral Arterial
Disease (PAD) Suffer High Rates of Heart Attack, Stroke,
Hospitalization, and Death |
| September 5 |
Taxus Woman Study Reports Positive Clinical Outcomes for the Taxus
Drug-eluting Stent in Women |
| September 5 |
Stimuvax Phase II Data Highlight Three-Year Survival Results for
Patients with Non-Small Cell Lung Cancer |
| September 5 |
Genasense Data in Melanoma to be Presented in Opening Session at
First Worldwide Melanoma Center Meeting of the European Association
of Dermato-Oncology |
| September 5 |
Patients Who Switched from Established Lipitor Therapy to
Simvastatin Experienced a Significant 30 Percent Increase in
Relative Risk of Cardiovascular Events or Death, New Observational
Study Shows |
| September 5 |
Pieris Validates the Use of Anticalins as Ophthalmologic
Biotherapeutics |
| September 5 |
Four Analyses of Three-Year Clinical Data Suggest CYPHER
Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery
for Patients with Multivessel Disease |
| September 5 |
Evotec Reports Details of the Positive Proof-of-Concept Phase II
Study in Insomnia With EVT 201 |
| September 5 |
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and
Anti-Arrhythmic Effects of Ranexa |
| September 5 |
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of
XL647 as First-Line Therapy for Non-Small Cell Lung Cancer |
| September 5 |
International Stem Cell Corporation Creates Human Cornea Tissue
from Its Parthenote Stem Cells; Preliminary Discovery Holds Promise
to Aid in Therapy for Blindness |
| September 5 |
Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical
Trials of Novel Investigational HIV Drug RDEA806 |
| September 5 |
Access and Somanta Announce New Data on Angiolix Humanized
Monoclonal Antibody |
| September 5 |
Stimuvax Therapeutic Cancer Vaccine – Phase II Data Highlight
Three-Year Survival Results for Lung Cancer Patients |
| September 5 |
Positive Survival Data from ASA404 Trial Presented at World
Conference on Lung Cancer |
| September 5 |
Genasense Data in Melanoma to be Presented in Opening Session at
First Worldwide Melanoma Center Meeting of the European Association
of Dermato-Oncology |
| September 5 |
DOR BioPharma Announces Publication Describing Protection Against
Oral and Aerosol Ricin Exposure With Its Ricin Vaccine RiVax |
| September 5 |
One of the Largest Post-WHI Physician Surveys Shows More Education
is Needed: Patient Misinformation About Hormone Therapy Remains
High |
| September 5 |
New Data Show Olmesartan, an Angiotensin Receptor Blocker (ARB) Has
Significant Anti-Atherosclerotic and Vascular Protective Effects |
| September 6 |
XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical
Inhibitors of Hepatitis C at an Upcoming International Scientific
Conference |
| September 6 |
Results from Study Evaluating Procrit in Intensive Care Unit
Patients Published in New England Journal of Medicine |
| September 6 |
The New England Journal of Medicine Publishes EURIDIS/ADONIS Study
Results Showing Dronedarone Maintained Sinus Rhythm in Patients
With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia |
| September 6 |
Idera Pharmaceuticals Presents Interim Data from Phase 1 Study
Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin |
| September 6 |
Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs,
Says Harvard Men's Health Watch |
| September 6 |
Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase
2b Data at Nine Months |
| September 6 |
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for
New Oncology Compound BIBW 2992 |
| September 6 |
New Flu Vaccine from PepTcell Could Provide Immunity Against All
Strains of Influenza Virus |
| September 6 |
Aranesp Study Showing No Negative Impact on Survival in SCLC
Presented at World Conference on Lung Cancer |
| September 6 |
Study Identifies Genetic Risk Factor for Rheumatoid Arthritis,
Lupus |
| September 6 |
Nymox BPH Drug Data Presentation September 8 at American Urological
Association Meeting |
| September 6 |
OSI Pharmaceuticals Announces Positive Results from a Metformin
Drug Interaction Study with Its DP-IV Inhibitor, PSN9301 |
| September 7 |
Arius Features Preclinical Data on Antibody Candidates at Two
Conferences |
| September 7 |
Genmab Announces Encouraging Preclinical Data for Ofatumumab |
| September 7 |
OSI Pharmaceuticals Summarizes Data Presented on Tarceva
(erlotinib) at the 12th World Congress on Lung Cancer Meeting |
| September 7 |
Pharmexa Presents New Data from Two Experimental Flu Vaccines on
International Vaccine Conference |
| September 7 |
Pharmaceuticals Holding AG Publication in LANCET Neurology
Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia |
| September 7 |
Protox To Present Interim Prostate Cancer Data at AUA Conference |
| September 7 |
Zemiva Normals Database From Molecular Insight Pharmaceuticals,
Inc. Enables Accurate Determination of Abnormal Heart Activity |
| September 7 |
Global Survey Reveals Significant Gap in Meeting World's Mental
Health Care Needs |
| September 7 |
Innogenetics Reports Top-line Results of Second Placebo-controlled
Clinical Trial with Candidate Hepatitis C Therapeutic E1 Vaccine |
| September 7 |
Peregrine Reports Data Showing Bavituximab's Potential to Shrink
Prostate Tumors |
| September 7 |
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin
Combination Therapy for Metastatic Breast Cancer Featured at Major
New Breast Cancer Symposium |
| September 7 |
Study Finds Heart Failure Is Rare Among Leukemia Patients on
Imatinib |
| September 10 |
Regeneron Announces Positive Results in Exploratory
Proof-of-Concept Study of Rilonacept in Chronic Active Gout |
| September 10 |
Outcomes Data Demonstrating Prognostic Value of Cytogen's
PROSTASCINT Published in Peer-Reviewed Journal Urology |
| September 10 |
R7128 Demonstrates Safety and Potent Antiviral Activity in
HCV-Infected Patients |
| September 10 |
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III
Prophylactic Trial for Hereditary Angioedema |
| September 10 |
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic
Breast Cancer |
| September 10 |
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42%
Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer
Trial |
| September 10 |
New Global Alliance Unveils Integrated Strategy to Combat Neglected
Diseases in The New England Journal of Medicine |
| September 10 |
XenoPort Announces Results of a Phase 1 Clinical Trial and Plans
for Additional Phase 2 Clinical Trials of XP19986 |
| September 10 |
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical
Trial of NGX267, a Selective M1 Agonist for the Potential Treatment
of Cognitive Impairment Associated with Schizophrenia |
| September 10 |
Data in the SinuNase Phase 3 Clinical Trial Predicts That Virtually
100% of Chronic Sinusitis Cases Are Due to a Fungal-Induced
Inflammation |
| September 10 |
MIGENIX to Present Positive Celgosivir Viral Resistance Data at
International HCV Meeting |
| September 10 |
Aspreva Provides Update On Lupus Nephritis Development Program |
| September 10 |
Chelsea Therapeutics Resolves Bioavailability Issue and Reports
Greater Than 10-Fold Improvement in Relative Bioavailability of New
CH-1504 Formulation |
| September 10 |
ValiRx - GeneICE & Cancer Research Technology Update |
| September 10 |
Nektar Presents Positive Results from Phase 1 Clinical Trial of
NKTR-118 (oral PEG-naloxol) at American College of Clinical
Pharmacology Meeting |
| September 10 |
Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens
Risk of Heart Disease |
| September 11 |
Lev Pharmaceuticals, Inc. Phase III Clinical Update Conference Call |
| September 11 |
NicOx Reports Topigen to Advance TPI-1020 Into Phase 2 for COPD
Following Promising Clinical Results |
| September 11 |
Trubion Announces Preliminary Analysis of Phase IIb Results With
TRU-015 in Rheumatoid Arthritis |
| September 11 |
Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal
Failure Patients at FDA Advisory Committee |
| September 11 |
Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to
Discuss the Phase IIb Clinical Trial of Bicifadine for the
Treatment of Diabetic Neuropathic Pain |
| September 11 |
Erbitux Meets Primary Endpoint of Increasing Survival in Phase III
Lung Cancer Study |
| September 11 |
S*BIO to Develop New JAK-2 Inhibitor for Treatment of
Myeloproliferative Disorders and Hematological Malignancies |
| September 11 |
Erbitux Meets Primary Endpoint of Increasing Survival in Phase III
Lung Cancer Study |
| September 11 |
Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine
Thrombin in Achieving Hemostasis in Surgery |
| September 11 |
Biothera's Imprime PGG Increases Efficacy of Erbitux against
Non-Small Cell Lung Cancer, Study Finds |
| September 11 |
Molecular Insight Pharmaceuticals, Inc. to Host Conference Call to
Review Positive Zemiva Phase 2b Data Presented at ASNC |
| September 11 |
Study Suggests Drug Used for Treatment for Heart Failure in Adults
May Not Be Beneficial for Children and Teens |
| September 11 |
Long-term Use of Glycemic Control Medication Rosiglitazone
Associated with Increased Risk of Heart Attack and Heart Failure |
| September 11 |
Glycemic Control Medication Pioglitazone Appears to Have Overall
Favorable Effect Regarding Risk of Cardiovascular Events |
| September 11 |
Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces
Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart
Failure |
| September 12 |
Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity
with HE3286 in Models of Diseases of Inflammation |
| September 12 |
Pharmacopeia Announces Positive Results from Phase 1 Multiple
Ascending Dose Study of PS433540 (DARA) |
| September 12 |
Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity |
| September 12 |
Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a
Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th
International Symposium on Hepatitis C Virus and Related Viruses |
| September 12 |
Targanta Therapeutics to Have Significant Presence at 47th Annual
ICAAC Meeting |
| September 12 |
Advitech Announces New Efficacy Results for Dermylex and Compliance
with FDA Regulations on Claims |
| September 12 |
Statistically Significant Efficacy of Juvista Demonstrated in Phase
2 Trial Using Drug Substance Manufactured by Lonza Biologics |
| September 12 |
AVI BioPharma Drug Demonstrates Strong Survival Benefits and
Elimination of Ebola Virus in Animals |
| September 12 |
Customized Virus Kills Brain Tumor Stem Cells that Drive Lethal
Cancer |
| September 12 |
GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS
Vaccine 2007 Conference |
| September 12 |
Cognitive Activities Protect Against Alzheimer's -- Social and
Physical Activities Not Enough |
| September 12 |
Manic Phase of Bipolar Disorder Benefits from Breast Cancer
Medication |
| September 12 |
New Topical Therapy Safely Treats Serious Skin Infections Without
Systemic Side Effects |
| September 13 |
BiDil Data to be Presented at Heart Failure Society of America
Science Meeting |
| September 13 |
Raptor Pharmaceuticals Provides Update of Product Programs |
| September 13 |
Optimer to Present Data on Lead Antibiotic Candidates at ICAAC |
| September 13 |
Vernalis Announces Striking Weight Loss in Phase I Study with
V24343 in Overweight and Mildly Obese Volunteers |
| September 13 |
Genasense Clinical Data in Patients with Advanced Melanoma and
Chronic Lymphocytic Leukemia to be Presented at ECCO Meeting in
Barcelona |
| September 13 |
Critical Therapeutics Announces Publication of Results from Two
Asthma Studies |
| September 13 |
Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In
Vitro Preclinical Studies in Leukemia Cells |
| September 13 |
Basilea Pharmaceutica Ltd. (CH) - New Data to be Presented on Key
Basilea Compounds at the Interscience Conference on Antimicrobial
Agents and Chemotherapy |
| September 13 |
Genmab Provides Insights into IgG4 Antibodies |
| September 14 |
Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal
Stents Yield Similarly Low Mortality Rates |
| September 14 |
Crucell N.V. (NL) - Crucell to present pre-clinical results for
H5N1 Virus treatment |
| September 14 |
Labopharm To Present Poster On Onset Of Analgesic Effect Of
Once-Daily Tramadol At Congress Of The European Society Of Regional
Anaesthesia And Pain Therapy |
| September 14 |
The Lancet Publishes Major Phase 3 Study on Novel Oral Direct
Thrombin Inhibitor |
| September 14 |
Basilea Announces Positive Top-line Data from Phase III Study of
Ceftobiprole in Community-acquired Pneumonia Requiring
Hospitalization |
| September 17 |
New Data for Galvus Provide Further Evidence of Robust Efficacy and
Tolerability in Treating Patients with Type 2 Diabetes |
| September 17 |
Immutep Announces That ImmuFact IMP321 Induces Activation of a Wide
Range of Human Effector Cytotoxic Cells |
| September 17 |
Trius Presents Study Results of Best-In-Class Antbiotics at ICAAC |
| September 17 |
Sygnis’ AX200 shows efficacy in stroke patients – Phase
IIa results exceed expectations |
| September 17 |
New Data for Galvus Provide Further Evidence of Robust Efficacy and
Tolerability in Treating Patients with Type 2 Diabetes |
| September 17 |
Ligand Announces Positive Preclinical Data on Selective Androgen
Receptor Modulator LGD-3303 |
| September 17 |
Cholesterol Byproduct Blocks Heart-health Benefits of Estrogen |
| September 17 |
Polydex Pharmaceuticals Limited announces BV Trial results |
| September 17 |
Oculus Innovative Sciences Microcyn Technology Data to be Presented
by Researchers at the 47th Interscience Conference on Antimicrobial
Agents and Chemotherapy |
| September 17 |
Pervasis Therapeutics Announces New Animal Study Results Supporting
Vascugel in Promoting Healing After Blood Vessel Injury |
| September 17 |
Risedronate Reduced Risk of Fracture Among Osteoporotic
Postmenopausal Women with History of Hip Fracture |
| September 17 |
Replidyne Pipeline Featured at 47th Annual Interscience Conference
on Antimicrobial Agents and Chemotherapy |
| September 17 |
Updated Revlimid Clinical Results Presented at the 12th
International Workshop on Chronic Lymphocytic Leukemia |
| September 17 |
Nanoviricides Go Beyond Antibodies in Fighting Bird Flu |
| September 17 |
Basilea Presents Research Data at ICAAC on Novel Antibiotic
Addressing the Emerging Threat from Multi-resistant Gram-negative
Bacteria |
| September 17 |
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and
Other TLR9 Agonists |
| September 17 |
Scientific Results Presented at ICAAC Demonstrate the
Well-differentiated Profile and Broad Spectrum of BioAlliance
Pharma's Antifungal |
| September 17 |
Study Presented on Use of Cancidas (caspofungin acetate) as
Empirical Therapy of Suspected Invasive Fungal Infections in
Pediatric Patients with Persistent Fever and Neutropenia |
| September 18 |
New Data Support Long-Term Efficacy and Safety in Patients Who Took
Exubera for Eight Years |
| September 18 |
First Osteoporosis Study in Patients with Hip Fracture Finds
Once-Yearly Aclasta-Reclast Prevents Additional Fractures and
Improves Survival |
| September 18 |
Aclidinium bromide demonstrates rapid and long-acting
bronchodilatory effect in COPD |
| September 18 |
Metabasis Therapeutics Presents Promising Preclinical Results with
Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes |
| September 18 |
First Osteoporosis Study in Patients with Hip Fracture Finds
Once-yearly Aclasta-reclast Prevents Additional Fractures and
Improves Survival |
| September 18 |
Study Presented on Use of Cancidas (caspofungin acetate) as
Empirical Therapy of Suspected Invasive Fungal Infections in
Pediatric Patients with Persistent Fever and Neutropenia |
| September 18 |
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma
Stopped Early Due to Highly Significant Efficacy Advantage of
Velcade (Bortezomib) for Injection Based Therapy Across All
Endpoints |
| September 18 |
Study Results for Aclidinium Bromide, a Novel Anticholinergic,
Presented at European Respiratory Society Annual Congress |
| September 18 |
Sosei Announces Completion of Phase II Trial of AD 337 in
Fibromyalgia Syndrome |
| September 18 |
Ardea Presents Early-Stage HIV Data at ICAAC |
| September 18 |
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates
Efficacy and Safety of Once-Daily PREZISTA/ritonavir vs. KALETRA as
Part of HIV Combination Therapy |
| September 18 |
New Data Show Doripenem as Effective as Commonly Used Therapies in
Treating Hospital-Acquired Pneumonias |
| September 18 |
Amicus Therapeutics Announces Plans to Present Phase 1 Data for
AT2220 for Pompe Disease |
| September 18 |
Data Presented at the 47th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is
a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent
Pharmacokinetics Suitable for Once-Daily Dosing |
| September 18 |
Isentress (raltegravir), in Combination with Optimized Background
Therapy (OBT), Provided Sustained Viral Suppression in Highly
Treatment-Experienced Patients Infected with HIV, through 48 Weeks |
| September 18 |
Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1
Metastatic Melanoma Study |
| September 18 |
Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves
High Immune Response at low Dosage |
| September 18 |
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's
New HIV Drug Selzentry (Maraviroc) |
| September 18 |
Study Demonstrates Aerosolized Prolastin Using Unique Nebulizer
Results in High Levels of Drug Deposited in Peripheral Regions of
Lungs |
| September 18 |
Results of Pre-Clinical Investigations of Ceragenix's Developmental
Antibiotic to Be Presented at International Scientific Meeting on
Infectious Diseases |
| September 18 |
Targeted Genetics Reports on Recombinant DNA Advisory Committee
(RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid
Arthritis |
| September 18 |
RDEA806, A Potent, New HIV NNRTI With a High Genetic Barrier to
Resistance and a Broad Spectrum of Activity, Introduced at 47th
ICAAC |
| September 18 |
Sangamo BioSciences Presents Data Demonstrating 'In Vivo'
Protection Against HIV Infection by CCR5-ZFN Therapeutic |
| September 18 |
New Data Show Ceftobiprole as Effective as Combination Therapy in
Treating Patients With Complicated Skin Infections, Including MRSA |
| September 19 |
Further Evidence for Lasting Immunological Efficacy of Diamyd
Diabetes Vaccine |
| September 19 |
Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at
the 10th International Conference on Endothelin |
| September 19 |
Acceleron Pharma Presents Positive Phase 1 Results Demonstrating
ACE-011 Increases Markers of Bone Formation |
| September 19 |
New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates
Efficacy And Safety Of Once-Daily Prezista/Ritonavir Vs. Kaletra As
Part Of HIV Combination Therapy |
| September 19 |
Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous
and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM)) |
| September 19 |
News on HIV Gene Therapy Clinical Trial at ICAAC |
| September 19 |
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of
RDEA806, a Novel NNRTI for HIV, at 47th ICAAC |
| September 19 |
New Data Show Ceftobiprole as Effective as Combination Therapy in
Treating Patients With Complicated Skin Infections, Including MRSA |
| September 19 |
Promising Early Data from Phase I/II Clinical Trial Using GenVec
Vaccine Presented at Malaria Conference |
| September 19 |
Results of Ceftobiprole Phase III Program for the Treatment of
Complicated Skin Infections Presented Today at ICAAC |
| September 19 |
CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with
Recombinant Hepatitis B Virus Protein |
| September 19 |
Biodel Inc. Announces VIAject Phase II Meal Study Data at the 2007
European Association for the Study of Diabetes Meeting |
| September 19 |
Enzo Biochem Reports Animal Study Supports Finding of New
Therapeutics for Treating Periodontal Bone Loss |
| September 19 |
Rimonabant Effectively Reduces Visceral Fat in the Obese Patient as
Confirmed by Abdominal Computer Tomography (ct) Scan |
| September 19 |
Appropriate Glycemic Control Contributes to Reducing the Risk of
Macrovascular Diseases in Patients with Diabetes |
| September 19 |
Astellas and Theravance Report Additional Telavancin Data at 47th
Annual ICAAC |
| September 19 |
New Phase III Data Presented for Once Monthly Dosing Regimen of
Risedronate to Treat Postmenopausal Osteoporosis |
| September 19 |
Increased Bone Mineral Density Seen in Phase IIB Study with
Odanacatib, Formerly MK-0822, An Investigational Cathepsin K
Inhibitor |
| September 19 |
Less Than One-Third of Women Aware of Landmark Hormone Therapy
Study, Stanford Researcher Finds |
| September 19 |
New Data From Large Safety Analysis of MYCAMINE Shows Favorable
Clinical Safety Profile |
| September 19 |
Preclinical Data on FermaVir's FV-100 Presented at the 47th Annual
Interscience Conference on Antimicrobial Agents and Chemotherapy |
| September 19 |
Metabasis Therapeutics Announces the First Publication on MB07811,
Its Novel Product Candidate for the Treatment of Hyperlipidemia, in
the Proceedings of the National Academy of Sciences |
| September 19 |
Teva Provides Update on Edratide for Systemic Lupus Erythematosus |
| September 19 |
Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75
Percent in Phase 2 Field Study |
| September 19 |
Targanta Presents First Data Demonstrating In Vitro Activity and In
Vivo Efficacy of Prodrugs in Osteomyelitis Models |
| September 19 |
Actos (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic
Cardiovascular Disease in Patients with Type 2 Diabetes |
| September 19 |
Arpida Presents Preclinical and Clinical Data on Iclaprim at Icaac |
| September 19 |
Eclipse Data on Effects of Otsuka's Investigational Novel
Treatment, Tolvaptan, on Advanced Heart Failure Patients'
Hemodynamics and Urine Output Featured in Heart Failure Society of
America's Late Breaking Trials |
| September 19 |
Dynavax's Heplisav Hepatitis B Vaccine Maintains Full
Immunogenicity at 50 Weeks in Phase 3 Trial |
| September 19 |
New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With
Other Routine Infant Vaccines in the U.S. |
| September 19 |
Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against
MRSA, VRE and Other Strains of Resistant Bacteria |
| September 19 |
Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin
and Metronidazole Against C. Difficile Bacteria |
| September 19 |
Replidyne's Investigational Antibacterial Agent REP3123 Prevents
Sporulation in Clostridium difficile |
| September 20 |
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an
Investigational Therapy for Osteoporosis |
| September 20 |
BioCryst Reports Preliminary Results From a Phase II Clinical Trial
of Peramivir in Subjects With Acute Influenza |
| September 20 |
New Study Shows Once-Monthly Boniva is as Clinically Effective as
Once-Weekly Fosamax at Increasing Bone Mineral Density in
Postmenopausal Women With Osteoporosis |
| September 20 |
Medivir: MIV-701 Preclinical Efficacy Data Presented |
| September 20 |
Arpida Presents Preclinical and Clinical Data on AR-709 at ICAAC |
| September 20 |
New Data Confirm Clear Benefit of Protelos (Strontium Ranelate) in
the Treatment of Postmenopausal Osteoporosis |
| September 20 |
Study Shows Vasopressin Receptor Antagonist Vaprisol (Conivaptan
Hydrochloride Injection) Significantly Increased Serum Sodium
Concentration in Patients with Euvolemic & Hypervolemic
Hyponatremia |
| September 20 |
Optimer Presents Positive Data on Two Lead Anti-Infective Drug
Candidates |
| September 20 |
Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone
Strength in Preclinical Studies in Non-Human Primates |
| September 20 |
Further Data on Safety and Efficacy of Cethromycin Presented at
47th Interscience Conference on Antimicrobial Agents and
Chemotherapy |
| September 20 |
Newly Published Phase II Study Shows the Investigational Drug
Vandetanib Prolongs Progression-Free Survival in Patients with
Advanced Non-Small Cell Lung Cancer (NSCLC) |
| September 20 |
A key sign of vascular aging, arterial stiffness, reduced by
leading blood pressure medication Diovan® |
| September 21 |
New Data Shows That the Unique Levemir Weight Benefit Continues
After Two Years of Treatment |
| September 21 |
Arpida Presents Preclinical Data on AR-2474 at ICAAC |
| September 21 |
One Year Study of Exenatide Treatment Showed Improved Beta-Cell
Function |
| September 21 |
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical
Trial for Painful HIV Distal Sensory Polyneuropathy |
| September 21 |
Amgen Oncology Highlights Upcoming Data Presentations at the 2007
European Conference on Clinical Oncology |
| September 21 |
The CYPHER Sirolimus-Eluting Coronary Stent Outperforms the Taxus
Stent in Small Coronary Vessels According to New Clinical Data
Analysis Published in the Journal of the American College of
Cardiology |
| September 24 |
Phase 3 Pivotal Trial of Tocosol Paclitaxel Does Not Meet Primary
Endpoint |
| September 24 |
Avastin Achieves Impressive Rate of Curative Surgery in Patients
With Advanced Colorectal Cancer |
| September 24 |
CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates |
| September 24 |
ChemGenex Announces Second Publication Demonstrating Activity of
Ceflatonin in T315I-Positive Chronic Myeloid Leukemia (CML) |
| September 24 |
Progen Announces PI-88 Phase 2 Lung Cancer Results |
| September 24 |
Current Chemotherapy Regimens for Advanced Colorectal Cancer
Prolong Survival |
| September 24 |
Nventa announces publication of HspE7 data |
| September 24 |
Summit plc Presents Zebrafish Data at International Safety Pharmacology Conference |
| September 25 |
Orexigen Announces Positive Clinical Results of Its Proprietary
Naltrexone Sustained Release Formulation for Use in Contrave |
| September 25 |
New Research Published on Impact of Targeting on Biodistribution
and Efficacy of siRNA Using Calando Pharmaceuticals' siRNA Delivery
Technology |
| September 25 |
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European College of Clinical Oncology Annual (ECCO) Meeting |
| September 25 |
Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial
Results of APD125 for the Treatment of Insomnia |
| September 25 |
Studies Suggest Key Correlation Between Lung Cancer Subtype and
Treatment Outcomes |
| September 25 |
Aranesp DAHANCA 10 Study Results Presented at ECCO Annual Meeting |
| September 25 |
New Biomarker Data Links KRAS Gene to Vectibix Clinical Response |
| September 25 |
Positive Xeloda Five-Year Overall Survival Study Data in the
Adjuvant Treatment of Colon Cancer Presented at Leading European
Cancer Meeting |
| September 25 |
Data from Phase II Study of Gilead's Darusentan in Resistant
Hypertension Published in Journal of Clinical Hypertension |
| September 25 |
DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions
in Drug- Compliant Subjects in Phase Ib Clinical Study |
| September 25 |
GlaxoSmithKline Reports Positive New and Updated Data on Tyverb
(lapatinib) at the 14th European Cancer Conference (ECCO) |
| September 25 |
Alpharadin Treatment More Than Doubles Survival Rate in Prostate
Cancer Patients |
| September 25 |
BioAlliance Pharma: Results Presented at ECCO 2007 Further Confirm
the Clinical Efficacy of BioAlliance Pharma's Antifungal,
Particularly in Populations with High Risk of Candidiasis |
| September 25 |
Survival Data Presented From Phase II Study of Investigational Drug
ZD4054 in Hormone-Resistant Prostate Cancer Patients |
| September 25 |
Data From Ongoing Hematological Trials With Darinaparsin Presented
at European College of Clinical Oncology Annual Meeting |
| September 25 |
Arpida’s Extensive Presence at ICAAC Well-Received |
| September 26 |
CollaGenex Pharmaceuticals Announces Results of Phase 2
Dose-Finding Study of Incyclinide for the Treatment of Rosacea |
| September 26 |
Positive Glufosfamide Results From a Phase 2 Clinical Trial
Presented at European Cancer Conference (ECCO) |
| September 26 |
Alkermes and Indevus Announce Positive Results from Phase 2a
Clinical Study of ALKS 27 for the Treatment of COPD |
| September 26 |
Herceptin Eradicates Tumours and May Reduce The Need for
Mastectomies in women with inflammatory HER2-Positive Breast Cancer |
| September 26 |
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at
American Academy of Pain Management Meeting |
| September 26 |
CollaGenex Pharmaceuticals Announces Results of Phase 2
Dose-Finding Study of Incyclinide for the Treatment of Rosacea |
| September 26 |
Phase 2 Study Suggests That Extended Dosing of Aranesp is as
Efficacious as Weekly Dosing |
| September 26 |
Promising Results in Treating Facial Bruising From Injectables |
| September 26 |
New Analysis Suggests First Cycle Use of Neulasta Reduces Febrile
Neutropenia Hospitalizations and Chemotherapy Dose Reductions in
Breast Cancer Patients Compared to Current Practice |
| September 26 |
New Phase III Data Demonstrate Oxycodone / Naloxone Combination
Tablet Reduces Opioid-induced Bowel Dysfunction in Patients with
Chronic Severe Pain |
| September 26 |
Incyte Reports Positive Proof-of-Concept Results For INCB18424, Its
Lead JAK Inhibitor, and INCB13739, its Lead 11beta-HSD1 Inhibitor |
| September 26 |
Alkermes and Indevus Announce Positive Results from Phase 2a
Clinical Study of ALKS 27 for the Treatment of COPD |
| September 26 |
New Preliminary Phase II Data Show Anti-Tumor Activity of
Single-Agent Sunitinib Malate in Advanced Gastric Cancer |
| September 26 |
New Phase III Data Demonstrate Oxycodone / Naloxone Combination
Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With
Chronic Severe Pain |
| September 26 |
Juvaris BioTherapeutics Announces Six Scientific Presentations at
Infectious Diseases Society of America (IDSA) Meeting October 6,
2007 |
| September 26 |
New Study Shows Promise for Hydrogen Sulfide in Reducing
Heart-Attack Damage, Ikaria Announces |
| September 26 |
Diamyd Diabetes Vaccine Effective for at Least 21 Months |
| September 26 |
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor
CXCR7 is Essential in Tumor Growth |
| September 26 |
Alnylam and Collaborators Publish New Paper in the Journal Nature
on the In Vivo Efficacy and Safety of RNAi Therapeutics |
| September 27 |
Introgen Presents Biomarker Data Demonstrating Abnormal p53
Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and
Li-Fraumeni Cancers |
| September 27 |
Pharmacopeia Confirms Blockade of Angiotensin II Response with
First-In-Class PS433540 (DARA) |
| September 27 |
Positive Clinical Data On MediciNova's Product Candidate MN-029
Presented At the 14th European Cancer Conference (ECCO 14) |
| September 27 |
Adventrx to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC
International Conference |
| September 27 |
Glufosfamide Results From Phase 3 Clinical Trial Presented at
European Cancer Conference (ECCO) |
| September 27 |
Nuvelo Announces Publication of NU206 Study Results in Proceedings
of the National Academy of Sciences of the United States of America |
| September 27 |
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor
Activity and Improved Pharmacokinetic Profile in Preclinical
Studies Presented at ECCO |
| September 27 |
Palatin Technologies, Inc. Reports Positive Data from an At-home
Study of Pre- and Postmenopausal Women with Female Sexual Arousal
Disorder Treated with Bremelanotide |
| September 27 |
ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus
Infected Primates |
| September 27 |
Study Shows Brostallicin in Combination with Cisplatin is
Well-Tolerated and Produces Prolonged Disease Stabilization in
Patients with Platinum-Resistant Cancers |
| September 27 |
Nymox Announces BPH Drug Clinical Data Presentation Sept. 28 at
American Urological Association Meeting |
| September 27 |
New Scientific Data on Allergan's Botox (Botulinum Toxin Type A)
Presented at the American Academy of Physical Medicine and
Rehabilitation 68th Annual Assembly |
| September 27 |
CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and
Deficits in Attention, Behavior Control, Verbal IQ |
| September 28 |
Crucell Discovers Human Monoclonal Antibodies for the Prevention
and Treatment of the Avian Flu Virus |
| September 28 |
Diffusion Pharmaceuticals Announces Results of Phase I Human Trial
of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and
Completion of a $4.5 Million Private Placement |
| September 28 |
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K.
Phase Ia/Ib Combination Reolysin and Radiation Clinical Trial |
| September 28 |
Genes Linked to Suicidal Thinking During Antidepressant Treatment |
